Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of pemetrexed + nedaplatin with concurrent thoracic IMRT for unresectable stage III lung adenocarcinoma
ChiCTR-OPN-16008316Phase 4Completed
- Sponsor
- The Sixth Affiliated Hospital, South China University of Technology
- Start
- Jan 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pemetrexed and nedaplatin in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The Sixth Affiliated Hospital, South China University of Technology. Primary endpoints: maximum tolerated dose, progression-free survival and 1 more. Started Jan 2012; status: completed.
02
Drugs
pemetrexednedaplatin
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPN-16008316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16008316.